Mersana Therapeutics Files 8-K Detailing Reverse Stock Split for Compliance

Rhea-AI Filing Summary

Mersana Therapeutics, Inc. (MRSN) has filed an 8-K disclosing that it will implement a 1-for-25 reverse stock split, effective 5:00 p.m. ET on 25 Jul 2025. Each block of 25 outstanding common shares will be reclassified into one share; fractional shares will be cashed out. The maneuver does not alter the company’s authorized share count or par value, but all equity incentive plan share pools and outstanding awards will be proportionally adjusted.

The reverse split is intended to restore compliance with Nasdaq’s $1.00 minimum bid price requirement, which the company previously flagged in its 2025 proxy. Post-split trading will commence on 28 Jul 2025 under the existing ticker “MRSN” with a new CUSIP of 59045L205.

No other material events, financial results or changes in fiscal year were reported. A copy of the Certificate of Amendment is attached as Exhibit 3.1.

Positive

• Regains Nasdaq compliance by boosting bid price above $1, avoiding potential delisting and related liquidity loss.
• No change to authorized share count or par value, preventing immediate dilution from the split itself.

Negative

• Reverse split signals sustained share-price weakness, which can erode investor confidence.
• Potential liquidity reduction as share count decreases, possibly widening spreads and increasing volatility.
• Unchanged authorized share cap leaves room for future share issuances that could dilute existing holders.

Insights

Equity Research Analyst

TL;DR: Reverse split averts delisting risk but signals persistent price pressure; valuation unchanged.

The 1-for-25 reverse split eliminates the imminent threat of a Nasdaq delisting by lifting the nominal share price above $1. While purely mechanical, such actions often reflect weak market sentiment and can decrease liquidity. Because authorized shares remain unchanged, potential future dilution capacity is intact. Absent operating updates, the split alone is neutral to intrinsic value, yet investors should monitor post-split bid-ask spreads and any subsequent capital-raising plans.

Corporate Governance Specialist

TL;DR: Governance compliant action, but reverse splits historically precede equity raises—watch dilution risk.

The company followed proper Delaware and SEC procedures, referencing prior shareholder authorization in the June proxy. Cash in lieu of fractional shares simplifies shareholder mechanics. However, maintaining the same authorized share pool keeps the board’s flexibility to issue shares, which, combined with a higher per-share price, can facilitate future financings that may dilute current holders. Overall governance execution is sound, but the market may interpret the move as a prelude to additional capital needs.

8-K Event Classification

3 items: 3.03, 5.03, 9.01

3 items

Item 3.03 Material Modification to Rights of Security Holders Securities

A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false --12-31 0001442836 0001442836 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2025

MERSANA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38129		04-3562403
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

840 Memorial Drive Cambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 498-0020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	MRSN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.03 Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 24, 2025, Mersana Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation, as amended, (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on July 25, 2025 (the “Effective Time”), a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).

The Reverse Stock Split is intended, among other things, to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market, as previously reported in the Company’s definitive proxy statement for the Company’s annual meeting of stockholders held on June 12, 2025, as filed with the Securities and Exchange Commission on April 29, 2025 (the “Proxy Statement”).

At the Effective Time, every twenty-five shares of issued and outstanding Common Stock will be automatically reclassified and combined into one share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to a fractional share of Common Stock are instead entitled to receive a cash payment in lieu of such fractional shares.

The Reverse Stock Split will not change the number of authorized shares of Common Stock or the par value of the Common Stock. Proportionate adjustments will be made to the number of shares of Common Stock available for issuance under the Company’s equity incentive plans, as well as the number of shares underlying, and the exercise prices of, outstanding equity awards under such plans, in accordance with their respective terms and as described in the Proxy Statement.

The Common Stock is expected to begin trading on a post-Reverse Stock Split basis at the market open on July 28, 2025 under the Company’s existing trading symbol “MRSN”. The new CUSIP number for the Common Stock following the Reverse Stock Split is 59045L205.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
3.1	Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation, as amended, of Mersana Therapeutics, Inc.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MERSANA THERAPEUTICS, INC.
Date: July 24, 2025	By:	/s/ Brian DeSchuytner
		Brian DeSchuytner
		Senior Vice President, Chief Operating Officer and Chief Financial Officer

FAQ

Why did Mersana Therapeutics (MRSN) execute a 1-for-25 reverse stock split?

To raise its share price above Nasdaq’s $1.00 threshold and maintain listing compliance.

When does Mersana's reverse split take effect and begin trading?

The split is effective 25 Jul 2025 at 5:00 p.m. ET; post-split trading starts 28 Jul 2025.

Will Mersana issue fractional shares after the split?

No; fractional positions will be settled with a cash payment.

Does the reverse split change the number of authorized shares or par value?

No, authorized share count and the $0.0001 par value remain the same.

What is the new CUSIP number for MRSN common stock?

Post-split shares will trade under CUSIP 59045L205.